Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer.

Abstract

BackgroundImmunotherapy is considered as a powerful and promising clinical approach for the treatment of gastric cancer (GC). However, it is still challenging to precisely screen patients who potentially benefit from immune checkpoint therapy (ICT). Identification of potential biomarkers for selecting patients sensitive to immunotherapy was urgently needed.MethodsPublic sequence data and corresponding clinical data were used to explore the potential biomarkers for immunotherapy.ResultsWe found that CSMD1 is the most frequently mutated gene and its mutation is highly correlated with prognosis in gastric cancer patients. Interestingly, patients with mutated CSMD1 exhibit a high mutation burden and upregulated PDL1 expression. The ratio of microsatellite instability (MSI) in the CSMD1 mutation cohort was higher than that in the cohort without CSMD1 mutation. Furthermore, patients with CSMD1 mutation have been found to possess a higher number of activated CD4+ T cells and neoantigens.ConclusionCSMD1 mutation may act as a novel biomarker for assessing the survival and immune therapy response in patients with gastric cancer.